ClinicalTrials.gg
CompletedNCT04725890REGENT-1Updated Jan 22, 2026Results posted

Safety and Feasibility of a Novel Endoscopic Intervention for the Treatment of Type II Diabetes

An interventional study of The DyaMX Device in Type 2 Diabetes, sponsored by Endogenex, Inc.. Completed at 2 sites in Australia. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by Endogenex, Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
65
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 262 studies in Diabetes Mellitus, Type 2 with a site in Australia — 24 open to participants now, 30 under way, 13 of them phase 3. Diabetes Mellitus, Type 2 · Australia.

Enrollment
202nd of 246
65 · median 392
Started
2021
with 5 others
No phase
31 of 262
4 open now
Registered
209th of 262
by date

Among the 262 studies in Diabetes Mellitus, Type 2 with a site in Australia, this one is the 202nd largest by enrollment of the 246 interventional ones that give a count, is one of 6 that started in 2021, is one of 31 with no phase, and was the 209th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

24 of the 262 studies in Diabetes Mellitus, Type 2 with a site in Australia are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 262 studies in Diabetes Mellitus, Type 2 with a site in Australia, or all of them as a file.
02

Study summary

This is an open-label study to assess the safety and feasibility of the DyaMX device for endoscopic duodenal mucosal regeneration in individuals with type 2 diabetes inadequately controlled on glucose-lowering medications.

Read the detailed description

Individuals who sign the informed consent will be screened for study eligibility. Eligible participants will be treated with the DyaMX procedure and followed up for 48 weeks.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18-70 years of age
  2. Current diagnosis of T2D
  3. History of T2D for less than or equal to 10 years, or use insulin for less or equal to 10 years
  4. of 7.5-11.0%
  5. 24-40 kg/m2
  6. If treated with non-insulin glucose lowering mediations, the medications (1-4 medications) should be stable for at least 12 weeks prior to baseline visit. If treated with basal insulin, the daily insulin dose should be within 20-60 IU.
  7. Agree not to donate blood during participation in the study.
  8. If treated with non-insulin glucose lowering medications, participant should have weight stability (defined as a \< 5% change in body weight) for at least 12 weeks prior to the screening visit
  9. Able to comply with study requirements and understand and sign the Form
  10. Women of must be using an acceptable method of throughout the study
  11. Willing and able to perform self-monitoring blood glucose and comply with study visits and study tasks as required per protocol.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosed with type 1 diabetes
  2. History of diabetic ketoacidosis or hyperosmolar nonketotic coma
  3. Probable insulin production failure, defined as overnight fasting C-peptide serum \<1 ng/mL (333pmol/l).
  4. Previous use of any types of insulin for >1 month (at any time, except for treatment of gestational diabetes) in last 2 years for those on non-insulin medications.
  5. Current use of multiple daily dose insulin or insulin pump
  6. Hypoglycemia unawareness
  7. History of ≥1 severe hypoglycemia (defined by needing for third-party assistance), unless a clear correctable precipitating factor can be identified, in past 6 months from the screening visit
  8. Known disease, as evidenced by a positive anti-glutamic acid decarboxylase (GAD) test, including but not limited to celiac disease, or pre-existing symptoms of systemic lupus erythematosus, scleroderma or other autoimmune connective tissue disorder.
  9. Previous GI surgery that has changed GI anatomy or could limit treatment of the duodenum, such as Billroth 2, Roux-en-Y gastric bypass, gastric band or other similar procedures or conditions.
  10. Known history of a structural or functional disorder of the upper GI tract that may impede passage of the device through the upper GI tract or increase risk of tissue damage during an endoscopic procedure, including esophagitis, stricture/stenosis, varices, diverticula, or other disorder of the esophagus, stomach and duodenum.
  11. Active H. pylori infection (Participants with active H. pylori may continue with the screening process if they are treated with an appropriate antibiotic regimen)
  12. History of, or gastrointestinal symptoms suggestive of gastroparesis.
  13. Acute gastrointestinal illness in the previous 7 days
  14. Known history irritable bowel syndrome, radiation enteritis or other inflammatory bowel disease, such as Crohn's disease and Celiac disease
  15. History of chronic or acute pancreatitis.
  16. Known active hepatitis or active liver disease other than NASH/NAFLD.
  17. Alcoholic liver disease, as indicated by ANI >0
  18. Current use of anticoagulation therapy (such as warfarin) that cannot be discontinued for 7 days before and 14 days after the procedure.
  19. Current use of P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) that cannot be discontinued for 14 days before and 14 days after the procedure.
  20. Unable to discontinue non-steroidal anti-inflammatory drugs (NSAIDs) during treatment through 4 weeks following the procedure. Use of acetaminophen and low dose aspirin is allowed.
  21. Use of systemic (excluding topical or ophthalmic application or inhaled forms) for more than 10 consecutive days within 12 weeks prior to the baseline visit.
  22. Use of drugs known to affect GI motility (e.g. Metoclopramide)
  23. Use of weight loss medications such as Phentermine, Meridia, Xenical, or over-the-counter weight loss medications (prescription medication)
  24. Persistent anemia, defined as \<10 g/dL.
  25. Known history of blood donation or transfusion within 3 months prior to the Screening Visit.
  26. Known history of cardiac arrhythmia
  27. Significant cardiovascular disease, including known history of valvular disease, or myocardial infarction, heart failure, , or stroke within 6 months prior to the Screening Visit.
  28. Estimated (eGFR) ≤ 30 ml/min/1.73m2.
  29. Known status, including but not limited to individuals who have undergone organ transplantation, chemotherapy, or radiotherapy within the past 12 months, who have clinically-significant leukopenia, who are positive for the (HIV) or whose immune status makes the participant a poor candidate for clinical trial participation in the opinion of the investigator.
  30. With any implanted electronic devices or duodenal metallic implants
  31. Not a candidate for upper GI endoscopy or general anesthesia.
  32. Active illicit substance abuse or alcoholism (> 2 drinks/day regularly).
  33. Active within the last 5 years (excluding non-melanoma skin cancers)
  34. Women breast feeding
  35. Participating in another ongoing clinical trial of an drug or device.
  36. Any other mental or physical condition which, in the opinion of the study investigator, makes the participant a poor candidate for clinical trial participation.
  37. Critically ill or has a \<3 years

    Additional exclusion criteria to be confirmed during the screening process:

  38. \< 7.5% or > 11% at baseline visit
  39. Any severe hypoglycemic event since the screening visit
  40. Glucose level \<54 mg/dl (3.0 mmol/l) in more than 1% of time by CGM since the screening visit
  41. Uncontrolled hyperglycemia with a glucose level >270 mg/dl (>15 mmol/L) after an overnight fast or >360 mg/dl (>20 mmol/l) in a randomly performed measurement that is confirmed by a second measurement (not on the same day) since screening visit
  42. Mean of 3 separate blood pressure measurements >180 mmHg (systolic) or >100 mmHg (diastolic)
  43. Women of with a positive urine pregnancy test at baseline visit
  44. Grade III or greater esophagitis on endoscopy
  45. Abnormalities of the GI tract preventing endoscopic access to the duodenum
  46. Anatomic abnormalities in the duodenum that would preclude the completion of the treatment procedure, including tortuous anatomy
  47. Endoscopic observation of upper gastrointestinal abnormality such as ulcers, polyps, varices, strictures, congenital or intestinal telangiectasia
  48. Any other anatomical or endoscopic abnormalities/characteristics that, in the opinion of the investigator, would preclude safe use of the investigational device or procedure.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Intervention

    All eligible participants will receive the DyaMX procedure.

    Device: The DyaMX Device

Interventions

  • DeviceThe DyaMX Device

    The DyaMX device is designed to induce duodenal mucosal regeneration using pulsed electric field. The DyaMX procedure is a non-surgical, endoscopic procedure.

    Also known as: Duodenal Mucosal Regeneration

06

What researchers measure

Primary outcomes

  1. Number of Participants With Device- or Procedure-related Serious Adverse Events (SAE)

    Number of participants experiencing one or more device- or procedure-related serious adverse events at 12 weeks post procedure

    Time frame: At 12 weeks post procedure

Secondary outcomes

  1. HbA1c by Post Procedure Follow-up Visit

    Mean HbA1c (%) by Post Procedure Follow-up Visit. The unit of measure for HbA1c is %.

    Time frame: Follow up at 12, 24, and 48 weeks post procedure

  2. Fasting Plasma Glucose by Visit

    Mean Fasting Plasma Glucose by Visit

    Time frame: Baseline, 12, 24, and 48 weeks

  3. Weight by Visit

    Mean Weight by Visit

    Time frame: Baseline, 12, 24, and 48 weeks

Other outcomes

  1. Procedural Success

    Percentage of participants with successful DMR procedure

    Time frame: At the time of the Index Procedure

  2. Procedural Time

    Time between catheter insertion to catheter removal

    Time frame: Time of Procedure

07

Results

Posted Jan 22, 2026
Limitations and caveats
This pilot study was performed to provide an early assessment of safety of the Endogenex device in participants with Type 2 Diabetes. Due to the small sample size, formal hypothesis testing was not performed and data may be limited to descriptive statistics, including mean and standard deviations.

Participant flow

Participants were recruited from 3 medical centers in Australia between January of 2021 and November of 2023. Participants were considered enrolled in the study once they passed endoscopic screening. Screen failures were defined as participants who consented for the study, started the screening process but were not subsequently enrolled. The first participant was enrolled on 20-Apr-2021 and the last on 27-Jul-2023.

Participant flow — Overall Study
MilestoneIntervention- Endogenex (PEF) Treatment
Started65
Completed59
Not completed6
Withdrew: Lost to follow-up2
Withdrew: Withdrawal by subject3
Withdrew: Physician decision1

Outcome measures

PrimaryNumber of Participants With Device- or Procedure-related Serious Adverse Events (SAE)

Number of participants experiencing one or more device- or procedure-related serious adverse events at 12 weeks post procedure

Time frame:
At 12 weeks post procedure
Reported as:
Count of participants · Participants
Number of Participants With Device- or Procedure-related Serious Adverse Events (SAE)
ParticipantsIntervention- Non-Insulin CohortIntervention- Insulin Cohort
Number of Participants With Device- or Procedure-related Serious Adverse Events (SAE)01
SecondaryHbA1c by Post Procedure Follow-up Visit

Mean HbA1c (%) by Post Procedure Follow-up Visit. The unit of measure for HbA1c is %.

Time frame:
Follow up at 12, 24, and 48 weeks post procedure
Reported as:
Mean · HbA1c %
HbA1c by Post Procedure Follow-up Visit
HbA1c %Intervention- Non-Insulin CohortIntervention- Insulin Cohort
Mean HbA1c at Baseline8.8 ± 0.98.5 ± 0.8
Mean HbA1c at 12 Weeks7.7 ± 1.27.9 ± 0.99
Mean HbA1c at 24 Weeks7.8 ± 2.48.1 ± 1.0
Mean HbA1c at 48 Weeks7.7 ± 2.47.6 ± 1.0
SecondaryFasting Plasma Glucose by Visit

Mean Fasting Plasma Glucose by Visit

Time frame:
Baseline, 12, 24, and 48 weeks
Reported as:
Mean · mmol/L
Fasting Plasma Glucose by Visit
mmol/LIntervention- Non-Insulin CohortIntervention- Insulin Cohort
Mean FPG at Baseline10.1 ± 2.78.6 ± 1.6
Mean FPG at 12 Weeks8.4 ± 2.38.3 ± 2.3
Mean FPG at 24 Weeks7.6 ± 2.68.8 ± 2.9
Mean FPG at 48 Weeks7.9 ± 3.17.5 ± 1.9
SecondaryWeight by Visit

Mean Weight by Visit

Time frame:
Baseline, 12, 24, and 48 weeks
Reported as:
Mean · kg
Weight by Visit
kgIntervention- Non-Insulin CohortIntervention- Insulin Cohort
Mean Weight at Baseline94 ± 1580 ± 12
Mean Weight at 12 Weeks90 ± 1479 ± 11
Mean Weight at 24 Weeks86 ± 3277 ± 12
Mean Weight at 48 Weeks89 ± 3073 ± 12
Other pre-specifiedProcedural Success

Percentage of participants with successful DMR procedure

Time frame:
At the time of the Index Procedure
Reported as:
Count of participants · Participants
Procedural Success
ParticipantsIntervention- Non-Insulin CohortIntervention- Insulin Cohort
Procedural Success5114
Other pre-specifiedProcedural Time

Time between catheter insertion to catheter removal

Time frame:
Time of Procedure
Reported as:
Mean · Minutes
Procedural Time
MinutesIntervention- Non-Insulin CohortIntervention- Insulin Cohort
Procedural Time74.3 ± 31.7102.5 ± 36.5

Adverse events

Collected over Baseline through 48 Weeks (duration of the study). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Intervention- Endogenex (PEF) Treatment0/65 (0%)5/65 (7.7%)58/65 (89.2%)
Most frequent serious events
Most frequent serious events
EventIntervention- Endogenex (PEF) Treatment
Colon CancerGastrointestinal disorders1/65
Cerebrovascular AccidentNervous system disorders1/65
Myocardial ischemiaCardiac disorders1/65
PyrexiaGeneral disorders1/65
TonsillitisInfections and infestations1/65
Celiac Artery stenosisGastrointestinal disorders1/65
PancreatitisGastrointestinal disorders1/65
Most frequent other events
Showing 10 of 74
Most frequent other events
EventIntervention- Endogenex (PEF) Treatment
COVID-19Infections and infestations26/65
Oropharyngeal painGastrointestinal disorders26/65
DiarrheaGastrointestinal disorders15/65
NauseaGastrointestinal disorders7/65
ConstipationGastrointestinal disorders6/65
Gastroesophageal reflux diseaseGastrointestinal disorders5/65
Adverse Drug ReactionGeneral disorders4/65
Abdominal painGastrointestinal disorders3/65
Back painMusculoskeletal and connective tissue disorders3/65
FlatulenceGastrointestinal disorders3/65

Baseline characteristics

Age, Continuous
Age, Continuous(years)Intervention- Non-Insulin CohortIntervention- Insulin CohortTotal
Mean52.8 ± 8.058.1 ± 7.053.9 ± 8.0
Sex: Female, Male
Sex: Female, Male(Participants)Intervention- Non-Insulin CohortIntervention- Insulin CohortTotal
Female13821
Male38644
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Intervention- Non-Insulin CohortIntervention- Insulin CohortTotal
Hispanic or Latino202
Not Hispanic or Latino491463
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Intervention- Non-Insulin CohortIntervention- Insulin CohortTotal
American Indian or Alaska Native000
Asian11213
Native Hawaiian or Other Pacific Islander101
Black or African American011
White35641
More than one race459
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Intervention- Non-Insulin CohortIntervention- Insulin CohortTotal
Australia511465
HbA1c
HbA1c(%)Intervention- Non-Insulin CohortIntervention- Insulin CohortTotal
Mean8.8 ± 0.98.5 ± 0.88.7 ± 0.9
Weight
Weight(Kg)Intervention- Non-Insulin CohortIntervention- Insulin CohortTotal
Mean93.6 ± 15.480.2 ± 11.890.7 ± 15.6
BMI (kg/m^2)
BMI (kg/m^2)(kg/m^2)Intervention- Non-Insulin CohortIntervention- Insulin CohortTotal
Mean31.5 ± 3.529.5 ± 4.231.1 ± 3.7

2 further baseline measures are reported on the registry.

08

Study locations

2 sites
  • The BMI Clinic
    Sydney, New South Wales 2028, Australia
  • St Vincent's Hospital Melbourne
    Fitzroy, Victoria VIC 3065, Australia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Mar 2024, 34 months.

Results were first posted in Jan 2026, 1 year 10 months after primary completion.

Of 177 industry-sponsored interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 29. This study's 34 months is above that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2021
First posted
Jan 27, 2021
StartActual
Apr 20, 2021
Primary completionActual
Mar 1, 2024
CompletionActual
Dec 22, 2024
Results first posted
Jan 22, 2026
Last update
Jan 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04725890
Lead sponsor
Endogenex, Inc.
Responsible party
Sponsor
First posted
Jan 27, 2021
Start date
Apr 20, 2021
Primary completion
Mar 1, 2024
Completion
Dec 22, 2024
Results posted
Jan 22, 2026
Last update
Jan 22, 2026

Study contacts

Adrian Sartoretto, MD
principal investigator · The BMI Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion